HSP90AA1 and cardiac hypertrophy: Research has indicated that pharmacological or genetic removal of Hsp90α or eHsp90α can reduce cardiac hypertrophy by inhibiting β-catenin/TCF7 signaling through N-cadherin-mediated pathways under pressure overload conditions.